Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Fluvastatin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HMGCR known ✓ | P04035 | 7/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 4/20 | 1.00 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 1.00 |
| ▸ | NR4A2 | P43354 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ABCC3 | O15438 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CCKAR | P32238 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC10A1 | Q14973 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.84 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.84 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluvastatin SCHEMBL464787 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL13501651 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL556754 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL628757 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL6268460 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL23468028 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2848 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL678274 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL2849 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D | |
| Fluvastatin SCHEMBL4295454 | 1.00 | HMGCR (1.00) | HMGCRCYP2C9SIRT6NR4A2PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 63012 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432447-B1 | — | — | None | — | — | US | claimed |
| US-20260144789-A1 | WOUND TREATMENTS AND COMPOSITIONS | CMPD LICENSING, LLC (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-122075699-A | Application of calcium activated chloride channel AN01/TMEM16A in preventing and treating atherosclerosis | — | 2026-05-26 | — | — | CN | claimed |
| US-12636273-B2 | Compositions for pathogenesis-directed therapy and treatments of skin diseases and disorders | YALE UNIVERSITY (US) | 2026-05-26 | — | — | US | claimed |
| US-12640239-B2 | Functional biomarkers for statin therapy in age-related macular degeneration (AMD) | APELIOTUS TECHNOLOGIES, INC. (US) | 2026-05-26 | — | — | US | claimed |
| WO-2026106952-A1 | METHODS FOR TREATING CONGENITAL DISORDERS OF GLYCOSYLATION | CDG CARE (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745160-A1 | METHOD FOR TREATING OR PREVENTING CHOLESTEROL-RELATED DISEASES USING PCSK9 INHIBITOR | Salubris (Chengdu) Biotech Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| US-20260124215-A1 | METHODS OF TREATMENT OF INTESTINAL INFECTIONS | THE FRANCIS CRICK INST LIMITED (GB) | 2026-05-07 | — | — | US | claimed |
| WO-1992020336-A2 | NOVEL CHOLESTEROL LOWERING COMPOUNDS | MERCK & CO., INC. (US) | 1992-11-26 | — | — | WO | claimed |
| EP-0512865-A2 | Novel cholesterol lowering compounds | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | claimed |
| EP-0508665-A2 | Use of ACE inhibitors for lowering serum cholesterol | E.R. SQUIBB & SONS, INC. (US) | 1992-10-14 | — | — | EP | claimed |
| WO-1992016276-A1 | PROCESS FOR PURIFICATION OF HMG-CoA REDUCTASE INHIBITORS | MERCK & CO., INC. (US) | 1992-10-01 | — | — | WO | claimed |
| US-5135935-A | Anticholesterol agents | MERCK & CO., INC. (US) | 1992-08-04 | — | — | US | claimed |
| EP-0482498-A2 | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1992-04-29 | — | — | EP | claimed |
| EP-0461548-A2 | Method for preventing a second heart attack employing and HMG CoA reductase inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-12-18 | — | — | EP | claimed |
| EP-0457514-A1 | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor | E.R. SQUIBB & SONS, INC. (US) | 1991-11-21 | — | — | EP | claimed |
| EP-0401705-A2 | Use of an HMG CoA reductase inhibitor and/or a squalene synthetase inhibitor for treating peripheral atherosclerotic disease | E.R. Squibb & Sons, Inc. (US) | 1990-12-12 | — | — | EP | claimed |
| US-4915954-A | Dosage form for delivering a drug at two different rates | ALZA CORPORATION (US) | 1990-04-10 | — | — | US | claimed |